Displaying 21 - 40 of 323
FTC, HHS Extend Public Comment Period on Generic Drug Shortages and Competition Request for Information
Date
The Â鶹´«Ã½ Trade Commission and the U.S. Department of Health and Human Services (HHS) are extending the deadline for the public to comment on a joint Request for Information (RFI) that seeks to...
FTC, HHS Seek Public Comment on Generic Drug Shortages and Competition Amongst Powerful Middlemen
Date
Today the Â鶹´«Ã½ Trade Commission (FTC) and the U.S. Department of Health and Human Services (HHS) jointly issued a Request for Information to understand how the practices of two types of...
FTC Submits Comment on March-In Rights to Promote Efforts to Lower Drug Prices
Date
Today the Â鶹´«Ã½ Trade Commission issued a comment in response to the National Institute of Standards and Technology’s (NIST) request for information on its Draft Interagency Guidance Framework for...
Statement on Second Circuit Order Upholding “Pharma Bro†Martin Shkreli’s Lifetime Ban
Date
Today, the United States Court of Appeals for the Second Circuit affirmed a district court ruling which ordered “Pharma Bro†Martin Shkreli to face a lifetime ban from participating in the...
Vyera Pharmaceuticals, LLC
The Â鶹´«Ã½ Trade Commission and a group of seven state enforcers filed a complaint in federal district court against Vyera Pharmaceuticals, LLC, alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim. The Commission vote to issue the complaint was 5-0. The complaint was filed on Jan. 27, 2020, in the U.S. District Court for the Southern District of New York. In a Jan. 14, 2022 ruling, U.S. District Court Judge Denise Cote found Shkreli’s conduct “egregious, deliberate, repetitive, long-running, and ultimately dangerous.†Judge Cote banned Shkreli for life from the pharmaceutical industry.
On January 23, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the U.S. District Court for the Southern District of New York’s ruling.
Type of Action
Â鶹´«Ã½
Last Updated
FTC Matter/File Number
161 0001
Case Status
Pending
Statement of Chair Lina M. Khan Joined by Commissioner Rebecca Kelly Slaughter In the Matter of Sanofi/Maze Therapeutics
Date
By
Lina M. Khan, Commissioner;
Rebecca Kelly Slaughter, Commissioner
Matter Number
D09422
File
Text of Statement
(126.92 KB)
Sanofi/Maze Therapeutics, Inc., In the Matter of
On December 13, 2023, the FTC moved to dismiss its case challenging the transaction following Sanofi’s decision to terminate its transaction with Maze Therapeutics Inc.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
2310091
Docket Number
9422
Case Status
Closed
FTC Approves Final Order Settling Horizon Therapeutics Acquisition Challenge
Date
The Â鶹´«Ã½ Trade Commission today finalized a consent order that resolves potential competitive harm stemming from Amgen Inc.’s acquisition of Horizon Therapeutics plc. As part of a nationwide...
Amgen, Inc. and Horizon Therapeutics plc, In the Matter of
In August 2023, the FTC reached a proposed consent order with Amgen Inc. to address the potential competitive harm that would result from Amgen’s $27.8 billion acquisition of Horizon Therapeutics plc. As part of a nationwide settlement of their challenge to the acquisition, the FTC and attorneys general from six states – California, Illinois, Minnesota, New York, Washington, and Wisconsin – also dismissed the related federal court preliminary injunction action, allowing the transaction to proceed, with the conditions imposed by the order. In December 2023, the FTC finalized the consent order with Amgen Inc. and appointed a monitor.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
231 0037
Docket Number
9414
Case Status
Closed
Statement Regarding the Termination of Sanofi’s Proposed Acquisition of Maze Therapeutics’ Pompe Disease Drug
Date
Following Sanofi’s decision to terminate its proposed acquisition of an exclusive license to Maze Therapeutics Inc.’s developmental drug to treat Pompe disease, the Â鶹´«Ã½ Trade Commission moved to...
FTC Seeks to Block Sanofi’s Acquisition of Rare Disease Drug that Threatens Sanofi’s Monopoly
Date
The Â鶹´«Ã½ Trade Commission is seeking to block Sanofi’s proposed acquisition of an exclusive license to Maze Therapeutics Inc.’s therapy in development for treatment of Pompe disease. The Commission...
Mylan Pharmaceuticals, et al. v. Sanofi-Aventis, et al.
Date
Citation Number
2:23-cv-00836-MRH
Â鶹´«Ã½ Court
Western District of Pennsylvania
File
FTC Files Amicus Brief Outlining Anticompetitive Harm Caused by Improper Orange Book Listings
Date
The Â鶹´«Ã½ Trade Commission filed an amicus brief to address the anticompetitive harm that stems from improperly listed patents in the Food and Drug Administration’s (FDA) publication of “Approved...
FTC Challenges More Than 100 Patents as Improperly Listed in the FDA’s Orange Book
Date
Today, the Â鶹´«Ã½ Trade Commission (FTC) challenged more than 100 patents held by manufacturers of brand-name asthma inhalers, epinephrine autoinjectors, and other drug products as improperly or...
FTC Staff Comment to Department of Labor on Proposed Amendments to Regulations Implementing the Mental Health Parity and Addiction Equity Act
Date
Matter Number
P184503
Docket Number
REG-120727-2
FTC Issues Policy Statement on Brand Pharmaceutical Manufacturers’ Improper Listing of Patents in the Food and Drug Administration’s ‘Orange Book’
Date
The Â鶹´«Ã½ Trade Commission today issued a policy statement , supported by the U.S. Food and Drug Administration (FDA), warning pharmaceutical companies that make and sell brand-name drugs that they...
Â鶹´«Ã½ Trade Commission Statement Concerning Brand Drug Manufacturers' Improper Listing of Patents in the Orange Book
Date
Matter Number
P233900
File
Text of the Policy Statement
(633.47 KB)
Displaying 21 - 40 of 323